Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells.

× No keyword cloud information.

11 in total

1. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia.

Authors: Varsha Gandhi; William Plunkett; Jorge E Cortes
Journal: Clin Cancer Res Date: 2014-02-05 Impact factor: 12.531

2. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.

Authors: Abhishek Maiti; Jorge Cortes; Alessandra Ferrajoli; Zeev Estrov; Gautam Borthakur; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Susan O'Brien; Hagop Kantarjian
Journal: Leuk Lymphoma Date: 2017-02-09

3. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.

Authors: Sanil Bhatia; Daniela Diedrich; Benedikt Frieg; Heinz Ahlert; Stefan Stein; Bertan Bopp; Franziska Lang; Tao Zang; Tobias Kröger; Thomas Ernst; Gesine Kögler; Andreas Krieg; Steffen Lüdeke; Hana Kunkel; Ana J Rodrigues Moita; Matthias U Kassack; Viktoria Marquardt; Friederike V Opitz; Marina Oldenburg; Marc Remke; Florian Babor; Manuel Grez; Andreas Hochhaus; Arndt Borkhardt; Georg Groth; Luitgard Nagel-Steger; Joachim Jose; Thomas Kurz; Holger Gohlke; Finn K Hansen; Julia Hauer
Journal: Blood Date: 2018-05-03 Impact factor: 22.113

Review 4. Cephalotaxus Alkaloids.

Authors: Joëlle Pérard-Viret; Laith Quteishat; Rana Alsalim; Jacques Royer; Françoise Dumas
Journal: Alkaloids Chem Biol Date: 2017-08-16

5. Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.

Authors: Seiichi Okabe; Tetsuzo Tauchi; Yuko Tanaka; Juri Sakuta; Kazuma Ohyashiki
Journal: Oncotarget Date: 2015-08-21

6. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology.

Authors: Vlad Moisoiu; Patric Teodorescu; Lorand Parajdi; Sergiu Pasca; Mihnea Zdrenghea; Delia Dima; Radu Precup; Ciprian Tomuleasa; Simona Soverini
Journal: Front Oncol Date: 2019-09-23 Impact factor: 6.244

7. Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.

Authors: Seiichi Okabe; Yuko Tanaka; Mitsuru Moriyama; Akihiko Gotoh
Journal: Cancer Chemother Pharmacol Date: 2020-01-04 Impact factor: 3.333

8. Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.

Authors: Seiichi Okabe; Tetsuzo Tauchi; Yuko Tanaka; Juri Sakuta; Kazuma Ohyashiki
Journal: J Hematol Oncol Date: 2015-08-04 Impact factor: 17.388

9. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.

Authors: Seiichi Okabe; Tetsuzo Tauchi; Shinya Kimura; Taira Maekawa; Toshihiko Kitahara; Yoko Tanaka; Kazuma Ohyashiki
Journal: PLoS One Date: 2014-02-28 Impact factor: 3.240

10. Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.

Authors: Seiichi Okabe; Tetsuzo Tauchi; Yuko Tanaka; Juri Sakuta; Kazuma Ohyashiki
Journal: Oncotarget Date: 2016-08-16